🔗 Share this article

An underground economy for unlicensed weight-loss medications is being driven by social media fitness personalities and vendors on communication apps, according to new investigations.

Experimental Drug Gaining Traction Online

Retatrutide, which remains in research studies, is being promoted by online personalities for its alleged weight-reducing properties. Viewers are urged to contact these profiles privately for source information, while also receiving promotional offers.

Active Commerce on Messaging Platforms

Additionally, a robust market exists on messaging services, where communities with numerous of members share “before and after” images, administration instructions and claims of next-day UK delivery. Vendors promote the substance there before directing customers to WhatsApp for transactions.

Understanding The Experimental Drug

This medication is an investigational injection created by US drugmaker Eli Lilly. The treatment targets three gut hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist patients lose up to 25% of their total weight. Nicknamed the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Healthcare Professionals Express Worries

However, doctors and pharmacists have warned that the sale of what is still an unlicensed drug in the United Kingdom is worrisome and could result in individuals injecting substances of unknown origin.

Some professionals said the popularity for retatrutide could be linked to the increasing price of approved weight loss products such as Mounjaro.

Regulatory Position and Enforcement

Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed medication that cannot be promoted or supplied for human use under the British medical regulations.

Several influencers attempt to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still violate pharmaceutical, marketing, and customer laws, risking penalties, prosecution or prison.

Platform Response and Content Removal

According to the social media company, the service has removed violative material and banned associated keywords and search suggestions. The company stated it was committed to maintaining the service safe and investing in strengthening enforcement strategies.

Digital Marketplace Activities

Research also discovered groups with up to nine thousand members marketing the experimental drug using Telegram's built-in discovery tool, which functions like a online catalog. Typing “retatrutide” instantly brings up groups with numerous of users, filled with photos of weight loss, positive reviews and step-by-step guides for mixing or injecting at residence.

After minutes of joining one community, a seller posted contact information, where the majority of purchases occur. The seller provided an instruction manual and guaranteed shipping within 48 hours. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None inquired about weight, medical conditions or previous experience.

Item Details and Pricing

Inside these groups, messages display dark colored packages with postal service labels, claiming to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at residence with sterile water, or ready-to-use injectors usually priced at 160 pounds for 20 milligrams. When asked how much time a pen should be used, sellers give contradictory answers varying between a few weeks to “depends on your body”.

Platform Oversight and Security Actions

A spokesperson for Telegram said it actively moderated harmful content on its platform including material that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are administering materials they cannot confirm. Even if the science behind this drug is sound, these digital versions may not include what they advertise,” stated a pharmacy expert, the head of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service connected the surge in interest to current cost increases for approved slimming drugs such as Mounjaro. “With costs increasing, patients are using social media. But fake treatments are highly dangerous. You can’t be certain what’s contained or whether the conditions they were made in was sterile,” she said.

Her team has previously seen individuals injured by self-injection from unverified sources. “We understand the disappointment, but purchasing from Telegram or communication platforms is taking chances with your health,” said the doctor. “These materials could be contaminated or improperly measured.”

Manufacturer Statement

A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency globally. “Therefore at this time no one can market [it] for human use,” they explained, adding that any item “falsely representing itself as a company experimental substance not yet authorized … may subject users to possibly significant health risks”.